{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:10:08Z","timestamp":1779304208274,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea","award":["NRF-2017R1D1A1B03033382"],"award-info":[{"award-number":["NRF-2017R1D1A1B03033382"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12933-019-0874-5","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T12:02:15Z","timestamp":1559304135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case\u2013control study"],"prefix":"10.1186","volume":"18","author":[{"given":"Min-Hee","family":"Woo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-9736","authenticated-orcid":false,"given":"Jinkwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"874_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5853\/jos.2018.03125","volume":"21","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kang K, Kang J, Koo J, Kim D-H, Kim BJ, et al. Executive summary of stroke statistics in Korea 2018: a report from the epidemiology research council of the Korean Stroke Society. J Stroke. 2019;21:42\u201359.","journal-title":"J Stroke."},{"key":"874_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.amepre.2007.01.021","volume":"32","author":"SP Kopunek","year":"2007","unstructured":"Kopunek SP, Michael KM, Shaughnessy M, Resnick B, Nahm E-S, Whitall J, et al. Cardiovascular risk in survivors of stroke. Am J Prev Med. 2007;32:408\u201312.","journal-title":"Am J Prev Med"},{"key":"874_CR3","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1161\/01.STR.0000133129.58126.67","volume":"35","author":"AJ Coull","year":"2004","unstructured":"Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004;35:1925\u20139.","journal-title":"Stroke"},{"key":"874_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/01.STR.0000057975.15221.40","volume":"34","author":"S-E Megherbi","year":"2003","unstructured":"Megherbi S-E, Milan C, Minier D, Couvreur G, Osseby G-V, Tilling K, et al. Association between diabetes and stroke subtype on survival and functional outcome 3\u00a0months after stroke: data from the European BIOMED Stroke Project. Stroke. 2003;34:688\u201394.","journal-title":"Stroke"},{"key":"874_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1586\/erc.10.98","volume":"8","author":"P de Pablos-Velasco","year":"2010","unstructured":"de Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther. 2010;8:1057\u201367.","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"874_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"874_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox R, Bousser M-G, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865\u201373.","journal-title":"Stroke"},{"key":"874_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000353679","volume":"36","author":"C-J Lu","year":"2013","unstructured":"Lu C-J, Sun Y, Muo C-H, Chen R-C, Chen P-C, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36:145\u201351.","journal-title":"Cerebrovasc Dis."},{"key":"874_CR9","first-page":"e15","volume":"46","author":"J Lee","year":"2017","unstructured":"Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46:e15.","journal-title":"Int J Epidemiol."},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1161\/STROKEAHA.117.018140","volume":"48","author":"J Kim","year":"2017","unstructured":"Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017;48:2723\u201330.","journal-title":"Stroke"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3988\/jcn.2016.12.1.42","volume":"12","author":"TH Park","year":"2016","unstructured":"Park TH, Choi JC. Validation of stroke and thrombolytic therapy in Korean National Health Insurance claim data. J Clin Neurol. 2016;12:42.","journal-title":"J Clin Neurol."},{"key":"874_CR12","first-page":"76","volume":"33","author":"JK Park","year":"2000","unstructured":"Park JK, Kim KS, Kim CB, Lee TY, Lee KS, Lee DH, et al. The accuracy of ICD codes for cerebrovascular diseases in medical insurance claims. Korean J Prev Med. 2000;33:76\u201382.","journal-title":"Korean J Prev Med."},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4070\/kcj.2012.42.1.10","volume":"42","author":"H Kimm","year":"2012","unstructured":"Kimm H, Yun JE, Lee S-H, Jang Y, Jee SH. Validity of the diagnosis of acute myocardial infarction in Korean National Medical health insurance claims data: the Korean Heart Study. Korean Circ J. 2012;42:10\u20135.","journal-title":"Korean Circ J."},{"key":"874_CR14","doi-asserted-by":"publisher","first-page":"e005025","DOI":"10.1136\/bmjopen-2014-005025","volume":"4","author":"SH Jee","year":"2014","unstructured":"Jee SH, Jang Y, Oh DJ, Oh B-H, Lee SH, Park S-W, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open. 2014;4:e005025.","journal-title":"BMJ Open"},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000177034","volume":"32","author":"HC Kim","year":"2009","unstructured":"Kim HC, Choi DP, Ahn SV, Nam CM, Suh I. Six-year survival and causes of death among stroke patients in Korea. Neuroepidemiology. 2009;32:94\u2013100.","journal-title":"Neuroepidemiology."},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1198\/000313005X70371","volume":"59","author":"SM Snapinn","year":"2005","unstructured":"Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan\u2013Meier estimator. Am Stat. 2005;59:301\u20137.","journal-title":"Am Stat"},{"key":"874_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35\u201344.","journal-title":"Stat Med"},{"key":"874_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0169-2607(94)01604-E","volume":"46","author":"AB Cantor","year":"1995","unstructured":"Cantor AB. A test of the association of a time-dependent state variable to survival. Comput Methods Programs Biomed. 1995;46:101\u20135.","journal-title":"Comput Methods Programs Biomed"},{"key":"874_CR19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/STROKEAHA.108.522557","volume":"40","author":"T Urabe","year":"2009","unstructured":"Urabe T, Watada H, Okuma Y, Tanaka R, Ueno Y, Miyamoto N, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke. 2009;40:1289\u201395.","journal-title":"Stroke"},{"key":"874_CR21","first-page":"43","volume":"3","author":"CV Desouza","year":"2010","unstructured":"Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights. 2010;3:43\u201351.","journal-title":"Clin Med Insights"},{"key":"874_CR22","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.116.024863","volume":"135","author":"LH Young","year":"2017","unstructured":"Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation. 2017;135:1882\u201393.","journal-title":"Circulation"},{"key":"874_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","volume":"137","author":"S Yaghi","year":"2018","unstructured":"Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke). Circulation. 2018;137:455\u201363.","journal-title":"Circulation"},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.5551\/jat.30007","volume":"22","author":"R Tanaka","year":"2015","unstructured":"Tanaka R, Yamashiro K, Okuma Y, Shimura H, Nakamura S, Ueno Y, et al. Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study. J Atheroscler Thromb. 2015;22:1305\u201316.","journal-title":"J Atheroscler Thromb."},{"key":"874_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee M, Saver JL, Liao H-W, Lin C-H, Ovbiagele B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke. 2017;48:388\u201393.","journal-title":"Stroke"},{"key":"874_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"M de Jong","year":"2017","unstructured":"de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR27","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"H-W Liao","year":"2017","unstructured":"Liao H-W, Saver JL, Wu Y-L, Chen T-H, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927.","journal-title":"BMJ Open"},{"key":"874_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.diabres.2015.06.005","volume":"109","author":"H Yokoyama","year":"2015","unstructured":"Yokoyama H, Araki S, Kawai K, Hirao K, Oishi M, Sugimoto K, et al. Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Res Clin Pract. 2015;109:485\u201392.","journal-title":"Diabetes Res Clin Pract"},{"key":"874_CR29","doi-asserted-by":"publisher","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","volume":"10","author":"J-M Seong","year":"2015","unstructured":"Seong J-M, Choi N-K, Shin J-Y, Chang Y, Kim Y-J, Lee J, et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS ONE. 2015;10:e0124287.","journal-title":"PLoS ONE"},{"key":"874_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-016-0350-4","volume":"15","author":"H-T Ou","year":"2016","unstructured":"Ou H-T, Chang K-C, Li C-Y, Wu J-S. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamaneurol.2017.2136","volume":"74","author":"WN Kernan","year":"2017","unstructured":"Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, et al. Targeting pioglitazone hydrochloride therapy after stroke or transient ischemic attack according to pretreatment risk for stroke or myocardial infarction. JAMA Neurol. 2017;74:1319\u201327.","journal-title":"JAMA Neurol."},{"key":"874_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0079","author":"JD Spence","year":"2019","unstructured":"Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2019.0079\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"874_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1210\/endo.142.3.8037","volume":"142","author":"JM Way","year":"2001","unstructured":"Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 2001;142:1269\u201377.","journal-title":"Endocrinology"},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.numecd.2009.07.010","volume":"21","author":"Y Tian","year":"2011","unstructured":"Tian Y, Yuan Z, Liu Y, Liu W, Zhang W, Xue J, et al. Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient mice. Nutr Metab Cardiovasc Dis. 2011;21:25\u201332.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"874_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.exger.2017.12.002","volume":"102","author":"D Shen","year":"2018","unstructured":"Shen D, Li H, Zhou R, Liu M-J, Yu H, Wu D-F. Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice. Exp Gerontol. 2018;102:101\u20138.","journal-title":"Exp Gerontol"},{"key":"874_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12933-017-0623-6","volume":"16","author":"Y Tian","year":"2017","unstructured":"Tian Y, Chen T, Wu Y, Yang L, Wang L, Fan X, et al. Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17\/Treg balance in AMPK-dependent mechanisms. Cardiovasc Diabetol. 2017;16:140.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/ATVBAHA.112.300346","volume":"33","author":"A Saremi","year":"2013","unstructured":"Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:393\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"70","key":"874_CR38","first-page":"881","volume":"2017","author":"OV Skochko","year":"1960","unstructured":"Skochko OV, Kaidashev IP. Effect of pioglitazone on insulin resistance, progression of atherosclerosis and clinical course of coronary heart disease. Wiadomosci Lek Wars Pol. 1960;2017(70):881\u201390.","journal-title":"Wiadomosci Lek Wars Pol"},{"key":"874_CR39","doi-asserted-by":"publisher","first-page":"520465","DOI":"10.1155\/2008\/520465","volume":"2008","author":"MA Deeg","year":"2008","unstructured":"Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res. 2008;2008:520465.","journal-title":"PPAR Res."},{"key":"874_CR40","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/ATVBAHA.107.150193","volume":"27","author":"S Qin","year":"2007","unstructured":"Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol. 2007;27:2428\u201334.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"874_CR41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.atherosclerosis.2011.07.112","volume":"218","author":"Y Shen","year":"2011","unstructured":"Shen Y, Yuan Z, Yin A, Liu Y, Xiao Y, Wu Y, et al. Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells. Atherosclerosis. 2011;218:330\u20138.","journal-title":"Atherosclerosis."},{"key":"874_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00592-018-01278-2","volume":"56","author":"G Sartore","year":"2019","unstructured":"Sartore G, Chilelli NC, Seraglia R, Ragazzi E, Marin R, Roverso M, et al. Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. Acta Diabetol. 2019;56:505\u201313.","journal-title":"Acta Diabetol"},{"key":"874_CR43","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.117.027952","volume":"135","author":"L Ryd\u00e9n","year":"2017","unstructured":"Ryd\u00e9n L, Mellbin L. New hope for people with dysglycemia and cardiovascular disease manifestations: reduction of acute coronary events with pioglitazone. Circulation. 2017;135:1894\u20136.","journal-title":"Circulation"},{"key":"874_CR44","first-page":"235","volume":"68","author":"R Kawamori","year":"2010","unstructured":"Kawamori R. Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone-special emphasis on PROactive Study and PERISCOPE Study. Nihon Rinsho Jpn J Clin Med. 2010;68:235\u201341.","journal-title":"Nihon Rinsho Jpn J Clin Med."},{"key":"874_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jcmg.2013.09.004","volume":"6","author":"Y Nitta","year":"2013","unstructured":"Nitta Y, Tahara N, Tahara A, Honda A, Kodama N, Mizoguchi M, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET\/CT imaging. JACC Cardiovasc Imaging. 2013;6:1172\u201382.","journal-title":"JACC Cardiovasc Imaging."},{"key":"874_CR46","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jcmg.2011.08.007","volume":"4","author":"M Mizoguchi","year":"2011","unstructured":"Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET\/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging. 2011;4:1110\u20138.","journal-title":"JACC Cardiovasc Imaging."},{"key":"874_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1507\/endocrj.K06-203","volume":"54","author":"H Maegawa","year":"2007","unstructured":"Maegawa H, Nishio Y, Nakao K, Ugi S, Maeda K, Uzu T, et al. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J. 2007;54:613\u20138.","journal-title":"Endocr J"},{"key":"874_CR48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/01.fjc.0000187176.13403.05","volume":"46","author":"FMAC Martens","year":"2005","unstructured":"Martens FMAC, Visseren FLJ, de Koning EJP, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"874_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-018-0663-6","volume":"17","author":"C-W Chan","year":"2018","unstructured":"Chan C-W, Yu C-L, Lin J-C, Hsieh Y-C, Lin C-C, Hung C-Y, et al. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018;17:20.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-017-0640-5","volume":"16","author":"C-Y Chang","year":"2017","unstructured":"Chang C-Y, Yeh Y-H, Chan Y-H, Liu J-R, Chang S-H, Lee H-F, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017;16:159.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-018-0773-1","volume":"17","author":"S Ida","year":"2018","unstructured":"Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. Cardiovasc Diabetol. 2018;17:129.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12933-018-0731-y","volume":"17","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Node K. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. Cardiovasc Diabetol. 2018;17:85.","journal-title":"Cardiovasc Diabetol."},{"key":"874_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3988\/jcn.2016.12.2.129","volume":"12","author":"OY Bang","year":"2016","unstructured":"Bang OY. Considerations when subtyping ischemic stroke in asian patients. J Clin Neurol. 2016;12:129\u201336.","journal-title":"J Clin Neurol."},{"key":"874_CR54","first-page":"685","volume":"3","author":"JK Lee","year":"2007","unstructured":"Lee JK, Grace KA, Foster TG, Crawley MJ, Erowele GI, Sun HJ, et al. How should we measure medication adherence in clinical trials and practice? Ther Clin Risk Manag. 2007;3:685\u201390.","journal-title":"Ther Clin Risk Manag"},{"key":"874_CR55","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/00005650-199909000-00002","volume":"37","author":"PW Choo","year":"1999","unstructured":"Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37:846\u201357.","journal-title":"Med Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0874-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0874-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0874-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:12:26Z","timestamp":1590793946000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0874-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0874-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The NHIS-NSC data was fully anonymized for privacy protection. Due to the retrospective nature and use of de-identified data, this study was approved, and informed consent was waived by the Institutional Review Board of Bundang CHA Medical Center (CHAMC 2018-12-032).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}